Anglo-Swedish pharma major AstraZeneca (LSE: AZN) has announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the USA for previously-treated adults with locally advanced or metastatic bladder cancer.
In May 2017, the PD-L1 inhibitor had been granted accelerated approval in the USA based on promising tumor response rates and duration of response data from Study 1108, a Phase I/II trial that evaluated the safety and efficacy of Imfinzi in advanced solid tumors, including previously-treated bladder cancer.
"The science of immunotherapy has moved swiftly over the past few years"Continued approval was contingent on results from the DANUBE Phase III trial in the first-line metastatic bladder cancer setting, which did not meet its primary endpoints in 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze